ALVAC gp100 / Sanofi - LARVOL DELTA

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control (Clin Cancer Res) - P3, N=676; NCT00094653; PMID: 23444228; Sponsor: Bristol-Myers Squibb; "Best overall response rates (complete responses plus partial responses) for 31 retreatment-eligible patients in the ipilimumab plus gp100 and ipilimumab plus placebo groups were 3/23 (13.0%) and 3/8 (37.5%), respectively and disease control rates were 65.2 and 75.0%."

P3 data • Melanoma • Oncology